kabutan

BrightPath Biotherapeutics Co., Ltd.(4594) Summary

4594
TSE Growth
BrightPath Biotherapeutics Co., Ltd.
69
JPY
-5
(-6.76%)
Mar 13, 3:30 pm JST
0.43
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
67.9
Mar 13, 11:59 pm JST
Summary Chart Historical News Financial Result
PER
PBR
8.35
Yield
ー%
Margin Trading Ratio
6.24
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
70 JPY 0.43 USD
Previous Close Mar 12
74 JPY 0.46 USD
High Mar 13, 9:00 am
71 JPY 0.44 USD
Low Mar 13, 9:06 am
67 JPY 0.42 USD
Volume
7,814,300
Trading Value
0.54B JPY 3.36M USD
VWAP
68.53 JPY 0.43 USD
Minimum Trading Value
6,900 JPY 43 USD
Market Cap
9.09B JPY 0.06B USD
Number of Trades
858
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
717
1-Year High Aug 15, 2025
10,957
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 1,419,400 18,801,900 13.25
Feb 27, 2026 1,396,900 17,629,200 12.62
Feb 20, 2026 1,398,900 18,089,800 12.93
Feb 13, 2026 1,395,200 17,106,500 12.26
Feb 6, 2026 1,380,100 17,765,100 12.87
Company Profile
BrightPath Biotherapeutics Co., Ltd. is a biotech venture originating from Kurume University, focusing on cancer immunotherapy using NKT cells and antibody drugs.
Sector
Pharmaceuticals
BrightPath Biotherapeutics Co., Ltd. is a drug discovery venture specializing in the development of cancer immunotherapy drugs, originating from Kurume University. The company has multiple pipelines ranging from exploratory research to early clinical trial stages, with a business model that generates revenue by licensing out to domestic and international pharmaceutical companies for late-stage clinical trials and beyond. Major development pipelines include iPS cell-derived NKT cell therapy, CAR-T cell therapy, antibody drugs, and personalized neoantigen vaccines. Notably, in the field of iPS cell-derived NKT cell therapy, the company exercised its option rights in November 2022 to acquire an exclusive development, manufacturing, and sales license from RIKEN, and is conducting the world's first clinical trial using iPS-NKT cells for head and neck cancer. Additionally, the company is advancing the development of CAR-T cell therapy for solid tumors. BrightPath Biotherapeutics is also developing antibody drugs targeting molecules that suppress cancer immunity, aiming to innovate cancer treatment through multiple approaches.